ALMS envudeucitinib misses SLE endpoints overall; strong IFNGS-high subgroup
Alms’ phase IIb LUMUS trial of envudeucitinib in SLE did not meet primary or secondary endpoints overall. The IFNGS-high subgroup showed robust efficacy for phase III focus; safety was favorable, with regulatory engagement planned by year-end.
The phase IIb LUMUS trial of envudeucitinib in SLE did not meet primary or secondary endpoints in the overall population, but showed robust efficacy in the IFNGS-high subgroup, which will be the focus for phase III.
Safety was favorable, and regulatory engagement is planned by year-end.Based on Alu…